130 related articles for article (PubMed ID: 6819145)
1. cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
Lund B; Aabo K; Rørth M; Hansen HH
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1089-92. PubMed ID: 6819145
[TBL] [Abstract][Full Text] [Related]
2. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
Vogl SE; Pagano M; Davis TE; Einhorn N; Tunca JC; Kaplan BH; Arseneau JC
Cancer Treat Rep; 1982 Jun; 66(6):1285-90. PubMed ID: 6282454
[TBL] [Abstract][Full Text] [Related]
3. cis-Platinum-hexamethylmelamine therapy of advanced ovarian cancer.
Lopez JA; Krikorian JG; Dias SF; Spiers AS; Finkel HE; Barnard DE
Gynecol Oncol; 1981 Feb; 11(1):64-7. PubMed ID: 6781990
[No Abstract] [Full Text] [Related]
4. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.
Legha SS; Buzdar AU; Hortobagyi GN; DiStefano A; Wiseman CL; Yap HY; Blumenschein GR; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):2053-6. PubMed ID: 118805
[TBL] [Abstract][Full Text] [Related]
5. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
Wiernik PH; Yeap B; Vogl SE; Kaplan BH; Comis RL; Falkson G; Davis TE; Fazzini E; Cheuvart B; Horton J
Cancer Invest; 1992; 10(1):1-9. PubMed ID: 1735009
[TBL] [Abstract][Full Text] [Related]
6. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group.
Lawson D; Moore M; Smalley R
Cancer Clin Trials; 1980; 3(4):293-6. PubMed ID: 6775826
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G
Oncology; 1982; 39(4):205-8. PubMed ID: 6806735
[TBL] [Abstract][Full Text] [Related]
10. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
11. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Stehman FB; Ehrlich CE; Callangan MF
Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
[TBL] [Abstract][Full Text] [Related]
12. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
13. Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
Brower MS; Coleman M; Pasmantier MW; Silver RT; Mamaril AP; Quiguyan CC
Med Pediatr Oncol; 1984; 12(1):17-24. PubMed ID: 6321930
[TBL] [Abstract][Full Text] [Related]
14. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
Vogl SE; Berenzweig M; Kaplan BH; Moukhtar M; Bulkin W
Cancer Treat Rep; 1979 Feb; 63(2):311-7. PubMed ID: 109202
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Kooyman CD; van Houwelingen JC; Pinedo HM
Cancer; 1984 Apr; 53(7):1467-72. PubMed ID: 6421472
[TBL] [Abstract][Full Text] [Related]
16. Alternating multiagent chemotherapy for advanced ovarian cancer.
Hernandez E; Rosenshein NB; Villar J; Dillon MB; Ettinger DS; Order SE
J Surg Oncol; 1983 Feb; 22(2):87-91. PubMed ID: 6296547
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
18. cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Krauss S; Tornyos K; DeSimone P; Lowenbraun S; McKeown J; Solomon A; Sonoda T
Cancer Treat Rep; 1979 Mar; 63(3):391-3. PubMed ID: 106964
[TBL] [Abstract][Full Text] [Related]
19. Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma.
Davis BW; Goldhirsch A; Locher GW; Dreher E; Greiner R; Burki K; Brunner KW
J Cancer Res Clin Oncol; 1984; 107(2):106-10. PubMed ID: 6325466
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
Frasci G; Comella G; Comella P; Conforti S; Mastrantonio P; Zullo F; Persico G
Gynecol Oncol; 1995 Jul; 58(1):68-73. PubMed ID: 7789893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
